A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
As the sciences of vascular access and infection prevention rapidly advance healthcare professionals are often faced with new technologies designed to help, but which are often so complicated to use that they cause unforeseen problems. As a vascular access team at a major mid-western hospital, we evaluated the ease-of-use and the performance characteristics of a new transparent catheter dressing, 3M Tegaderm CHG IV Securement Dressing ® (3M Health Care™, St. Paul, MN) containing thedoi:10.2309/java.13-1-4 fatcat:q3vnndixojddhhmbrmtbrks3h4
more »... ing the antimicrobial chlorhexidine gluconate (CHG), with a variety of central venous catheters insertion sites in comparison to a standard non-antimicrobial dressing Tegaderm ® (3M Health Care™, St. Paul, MN). Following IRB approval, sixty-three consenting patients were enrolled and randomized; 33 in the CHG antimicrobial dressing group and 30 in the standard dressing group. Thirty six patients had peripherally inserted central catheters (PICCs), 20 had intrajugular insertions (IJ), and 7 had subclavian insertions. The new 3M Tegaderm CHG IV Securement Dressing ® (3M Health Care™, St. Paul, MN) was evaluated for its ability to permit visualization of the insertion site, ease of use, ease of using correctly, ability to secure the catheter and absorb exudates and remain transparent. The new 3M Tegaderm CHG IV Securement Dressing ® (3M Health Care™, St. Paul, MN) was found to be as easy to use in central venous catheter care clinical practice as the standard of care non-antimicrobial transparent adhesive dressing. No additional training or education was required to properly use it. This dressing was applied and removed like standard transparent adhesive dressings, but offered many advantages over standard dressings. Advantages include that it is antimicrobial, handles moderate bleeding, remains transparent and appears to offer greater catheter securement than the Tegaderm ® (3M Health Care™, St. Paul, MN) standard dressing. The CHG gel pad also conformed well to the catheter.
A series of experiments by Olson, Maio, and Hobden (1999) tested this perception. ... Experiment 3 In a third experiment (Janes & Olson, 2009) , only creativ ity w as assessed. ...doi:10.5964/ejop.v6i3.208 fatcat:tywvlwpyoze5bpprvjfzkgkbwm
Bern, 1972; Olson, 1992; Olson & Zanna, 1993) . ... ., Bern, 1972; Olson, 1992 ; helping research reviewed above). ...doi:10.1037//0022-35188.8.131.52 fatcat:aildpy35qbfwtg3r4yckyy5epm
1992 Olson & Roese, 1995) . ... ., DePaulo, Stone, & Lassiter, 1985; Olson, 1988; Olson & Ross, 1988; Zuckerman & Driver, 1985) , but the aspect of attitude dissimulation that has received the most attention has been its effect on the ...doi:10.1006/jesp.1997.1348 fatcat:zlconcv3nbgqnl6bsdkpdybuwm
, Roese, Meen, & Robertson, 1995; Quinn, Roese, Pennington, & Olson, 1999; D.M. ... comparative judgments by starting with this knowledge as an anchor, while taking insufficient account of what other people are actually like (Clement & Krueger, 2000; Dunning & Hayes, 1996; Kruger, 1999; M. ...doi:10.1111/j.1745-6916.2007.00033.x pmid:18552989 pmcid:PMC2429993 fatcat:2wu5hoj42rhinpdpuuwtb3ax3i
Linda M. Montgomery & James N. Olson 3 For Veterans who graduated, the PCL-5 and DASS21 showed reduction of symptoms related to PTSD, depression, anxiety, and stress (see Table 1 ). ... , M = 18.50, SD = 4.77). ...doi:10.15640/jpbs.v6n1a1 fatcat:vihfifj3wvbldaka32hb3tdavm
Olson, J. M. Lang DOI: 10.4236/ojss.2020.109022 426 Open Journal of Soil Science ... Olson, J. M. Lang DOI: 10.4236/ojss.2020.109022 416 Open Journal of Soil Science aboriginal people of the Yukon River Basin may be among the oldest known residents of North America. ...doi:10.4236/ojss.2020.109022 fatcat:gq47btxqprf3hglcwqmfi65gw4
Both of these effects might occur through self-perception processes (e.g., Bern, 1972; Olson, 1990 Olson, , 1992 . ... condition (M = 0.27, SD = 0.24), t(138) = 5.70, p < .001. ...doi:10.1037//0022-35184.108.40.2064 fatcat:6bm3eni4zbawjnbss7i4miwf6u
Purpose of Review-Most children diagnosed with cancer today are expected to be cured. Medulloblastoma, the most common pediatric malignant brain tumor, is an example of a disease that has benefitted from advances in diagnostic imaging, surgical techniques, radiation therapy and combination chemotherapy over the past decades. An incurable disease 50 years ago, approximately 70% of children with medulloblastoma are now cured of their disease. However, the pace of increasing the cure rate hasdoi:10.1097/mop.0b013e32834ec106 pmid:22189395 pmcid:PMC3348176 fatcat:rowld4gfznhofnv3sqwcu4x2ie
more »... cure rate has slowed over the past two decades, and we have likely reached the maximal benefit that can be achieved with cytotoxic therapy and clinical risk stratification. Long-term toxicity of therapy also remains significant. To increase cure rates and decrease long-term toxicity, there is great interest in incorporating biologic "targeted" therapy into treatment of medulloblastoma, but this will require a paradigm shift in how we classify and study disease. Recent Findings-Using genome-based high-throughput analytic techniques, several groups have independently reported methods of molecular classification of medulloblastoma within the past year. This has resulted in a working consensus to view medulloblastoma as four molecular subtypes including WNT pathway subtype, SHH pathway subtype, and two less well-defined subtypes, Group C and Group D. Summary-Novel classification and risk stratification based on biologic subtypes of disease will form the basis of further study in medulloblastoma, and identify specific subtypes which warrant greater research focus.
Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran ... Agren M, Kogerman P, Kleman MI, Wessling M, Toftgard R. ...doi:10.1016/j.cancergencyto.2007.09.008 pmid:18068533 pmcid:PMC2219922 fatcat:7c6cnym5ofctzhu633arioq4oi
First, counterfactual thinking may be triggered by negative and unexpected outcomes (Kahneman & Miller, 1986; Olson, Roese, & Deibert, 1996; Roese & Olson, 1995a) . ... The means for the near-miss (M:55.6%) versus far-miss (M:55.5%) did not differ. ...doi:10.1006/jesp.1996.0010 fatcat:g5grpu2arffgjlugqvdwmqkkqy
REVIEW Despite enormous progress in elucidating the molecular pathology of Huntington disease (HD), the prognosis for patients has improved little since the first description of this disease in 1872. Nor have effective treatments been developed for other diseases caused by expanded polyglutamine repeats. However, in the past decade, non-human primate, mouse, Drosophila, Caenorhabditis elegans, yeast and tissue culture models have provided insights into the pathogenic mechanisms of thesedoi:10.1038/86486 pmid:11283667 fatcat:qmrddl5vuvgyhd4vc3ar5xfvjm
more »... ms of these Polyglutamine diseases comprise a class of familial neurodegenerative disorders caused by expression of proteins containing expanded polyglutamine tracts. Great progress has been made in elucidating the molecular mechanisms contributing to polyglutamine pathology, and in identifying potential drug targets. Although much remains to be learned, these advances provide an opportunity for rational approaches to target-based drug discovery.
Bern, 1972; Olson, 1992; Olson & Zanna, 1993) . ... ., Bern, 1972; Olson, 1992 ; helping research reviewed above). ...doi:10.1037/0022-35220.127.116.11 fatcat:qzg7dduni5hsxbzick5kekgkby
Both of these effects might occur through self-perception processes (e.g., Bern, 1972; Olson, 1990 Olson, , 1992 . ... condition (M = 0.27, SD = 0.24), t(138) = 5.70, p < .001. ...doi:10.1037/0022-3518.104.22.1684 fatcat:fuq2vqp4mnglhfuohdkjesxzfm
« Previous Showing results 1 — 15 out of 533 results